US-based clinical research organisation (CRO) Medpace has expanded its medical-device capabilities in Europe by acquiring MediTech Strategic Consultants for an undisclosed sum.
Founded in 2000 by president and chief executive officer (CEO) Carla Kikken-Jussen, MediTech has supported clinical trials of a wide range of medical devices in therapeutic areas such as ophthalmology, cardiovascular disease, gastroenterology, orthopedics and pulmonology.
Kikken-Jussen will continue to lead MediTech with her team members, bringing to Medpace extensive expertise that “complements and broadens our global medical device service offering”, noted the latter’s president and CEO Dr August Troendle.
Strategic acquisition
“MediTech is well respected in both Europe and the US, and this strategic acquisition fully supports Medpace’s growth and provides our sponsors a wide range of regulatory and clinical expertise across North America and Europe along with expanded operational capacity,” Troendle added.
A full-service contract research organisation focused on medical devices and combination products, MediTech fields a staff of more than 40, with headquarters in Vaals, the Netherlands; an office in Houston, US; and additional professionals on the ground in the Czech Republic, Israel and Poland.
The company specialises in steering medical devices to CE Mark approval, via regulatory consulting and clinical trials, and in post-marketing studies or registries.
Global solution
Combined with Medpace’s existing Medical Device division, the acquisition provides “a unique global solution for medical device development, allowing seamless support through all stages of the medical device lifecycle”, the company said.
Medpace already firmed up its device capabilities in March 2010 by acquiring by US-based specialist Symbios Clinical.
